Elicio Therapeutics, Inc. (ELTX) · Nov 5, 2026 · Other events

Elicio earnings sharpen Phase 3 path after Phase 2 miss

Refined Phase 3 strategy — Primary DFS endpoint missed; adjusted hazard ratio 0.47 (p=0.0086)

Elicio’s earnings update adds sharper Phase 3 selection data for camupepimut, but the core AMPLIFY-7P endpoint still failed and financing remains central.

Elicio is a clinical-stage biotech trying to turn camupepimut from a failed overall Phase 2 readout into a narrower, biomarker-guided pancreatic-cancer program. The June result already established that AMPLIFY-7P missed its primary endpoint and that the company needed more capital before launching Phase 3; today’s filing adds the subgroup detail and financing runway that determine whether that rescue strategy is credible.

The clinical signal is more usable, but not cleanly validated. The new analyses show lower recurrence-or-death risk across ctDNA-negative patients, ctDNA-positive patients, and patients without prior radiation, while the adjusted analysis estimates a 53% hazard reduction. But the headline limitation remains that the randomized study missed its primary DFS endpoint in the full intent-to-treat population. This strengthens the case for a targeted Phase 3 design; it does not restore the evidentiary strength of a clean overall win.

MeasureQ3 2026Q3 2025Comparison
Net loss (Financial Results)$8.0M$10.1M
Net loss/share (Financial Results)$0.30$0.60
R&D expense (Financial Results)$4.9M$5.0M
Cash and equivalents (Balance Sheets)$30.9M$18.6M at Dec. 31, 2025

The balance sheet now buys time, not proof. Elicio raised $4.3 million through its at-the-market program during the quarter and had already raised about $13.6 million in a July registered direct offering. The company now says cash supports operations into Q2 2027, extending the previously stated Q1 2027 runway, but the filing still points to a financing-dependent path for a future registrational trial. 〔0〕

The next operating test is execution on the narrower plan. Elicio is targeting a Q4 2026 Phase 1 study combining camupepimut with daraxonrasib, with or without nivolumab, in metastatic KRAS-mutated pancreatic cancer. 〔1〕 That program and the eventual Phase 3 design will show whether the subgroup findings become a development path or remain a post-hoc explanation for a failed trial.

Bottom line: This is a meaningful refinement of Elicio’s strategy, not a reversal of the Phase 2 miss. The business story improves modestly because the company has a more focused clinical path and more runway, but the central efficacy risk remains unresolved.

What to watch next

Q4 2026 metastatic PDAC Phase 1 initiation

Original filing on SEC EDGAR

Elicio earnings sharpen Phase 3 path after Phase 2 miss | ELTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.